Menu Search
Equities

Ligand Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LGDN:STU

Ligand Pharmaceuticals Inc

Actions
  • Price (EUR)95.00
  • Today's Change-1.00 / -1.04%
  • Shares traded0.00
  • 1 Year change+23.38%
  • Beta0.8934
Data delayed at least 15 minutes, as of Jul 04 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

  • Revenue in USD (TTM)181.49m
  • Net income in USD-132.62m
  • Incorporated1987
  • Employees68.00
  • Location
    Ligand Pharmaceuticals Inc3911 Sorrento Valley Blvd, Suite 110SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 550-7500
  • Fax+1 (302) 636-5454
  • Websitehttps://www.ligand.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LGND:NMQ since
announced		Transaction
value
APEIRON Biologics AGAnnounced08 Jul 202408 Jul 2024Announced35.81%100.00m
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.